Expression of ERCC1 antisense RNA abrogates gemcitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair

Clinical Cancer Research

Volumn 6, Issue 3, 2000, Pages 773-781

  Yang, Li Ying ^a,b   Li, Lan ^a   Jiang, Hong ^a   Shen, Yu ^a   Plunkett, William ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DNA; CISPLATIN; COMPLEMENTARY RNA; DEOXYADENOSINE TRIPHOSPHATE; DEOXYCYTIDINE TRIPHOSPHATE; DRUG METABOLITE; GEMCITABINE; HYGROMYCIN;

ARTICLE; BINDING COMPETITION; CANCER CELL CULTURE; COLON CARCINOMA; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DNA SYNTHESIS; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BASE PAIR MISMATCH; CELL SURVIVAL; CISPLATIN; COLONIC NEOPLASMS; DEOXYCYTIDINE; DEOXYCYTOSINE NUCLEOTIDES; DNA; DNA REPAIR; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG SYNERGISM; ENDONUCLEASES; GENE EXPRESSION; HUMANS; MUTATION; PROTEINS; RNA, ANTISENSE; TUMOR CELLS, CULTURED;

EID: 0034059127     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Storniolo, A. M., Enas, N. H., Brown, C. A., Voi, M., Rothenberg, M. L., and Schilsky, R. An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer (Phila.), 85: 1261-1268, 1999.
2. Sandler, A., and Ettinger, D. S. Gemcitabine: single-agent and combination therapy in non-small cell lung cancer. Oncologist, 4: 241-251, 1999.
3. Carmichael, J., Possinger, K., Philip, P., Beykirch M., Kerr, H., Walling, J., and Harris, A. L. Advanced breast cancer: a phase II trial with gemcitabine. J. Clin. Oncol., 13: 2731-2736, 1995.
4. Moore, M. J., Tannock, I. F., Ernst, D. S., Huan, S., and Murray, N. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J. Clin. Oncol., 15: 3441-3445, 1997.
5. Carmichael, J. Clinical response benefit in patients with advanced pancreatic cancer. Role of gemcitabine. Digestion, 58: 503-507, 1997.
6. Fossella, F. V., Lippman, S. M., Shin, D. M., Tarassoff, P., Calayang-Jung, M., Perez-Soler, R., Lee, J. S., Murphy, W. K., Glisson, B., Rivera, E., and Hong, W. K. Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naïve patients with advanced non-small-cell lung cancer. J. Clin. Oncol., 15: 310-316, 1997.
7. Friedlander, M., Millward, M. J., Bell, D., Bugat, R., Harnett, P., Moreno, J. A., Campbell, L., Varette, C., Ripoche, V., and Kayitalire, L. A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann. Oncol., 9: 1343-1345, 1998.
8. Zinzani, P. L., Magagnoli, M., Bendandi, M., Orcioni, G. F., Gherlinzoni, F., Albertini, P., Pileri, S. A., and Tura, S. Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Ann. Oncol., 9: 1351-1353, 1998.
9. Einhorn, L. H., Stender, M. J., and Williams, S. D. Phase II trial of gemcitabine in refractory germ cell tumors. J. Clin. Oncol., 17: 509-511, 1999.
10. Cardenal, F., lopez-Cabrerizo, M. P., Anton, A., Alberola, V., Massuti, B., Carrato, A., Barneto, I., Lomas, M., Garcia, M., Lianes, P., Montalar, J., Vadell, C., Gonzalez-Larriba, J. L., Nguyen, B., Artal, A., and Rosell, R. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol., 17: 12-18, 1999.
11. Bergman, A. M., Ruiz van Haperen, V. W. T., Veerman, G., Kuiper, C. M., and Peters, G. J. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin. Cancer Res., 2: 521-530, 1996.
12. van Moorsel, C. J., Pinedo, H. M., Veerman, G., Bergmen, A. M., Kuiper, C. M., Vermorken, J. B., van der Vijgh, W. J., and Peters, G. J. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br. J. Cancer, 80: 981-990, 1999.
13. Theodossiou, C., Cook, J. A., Fisher, J., Teague, D., Liebmann, J. E., Russo, A., and Mitchell, J. B. Interaction of gemcitabine with paclitaxel and cisplatin in human tumor cell lines. Int. J. Oncol., 12: 825-832, 1998.
14. Braakhuis, B. J., Ruiz van Haperen, V. W., Welters, M. J., and Peters, G. J. Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts. Eur. J. Cancer, 31A: 2335-2340, 1995.
15. van Moorsel, C. J. A., Pinedo, H. M., Veerman, G., Vermorken, J. B., Postmus, P. E., and Peters, G. J. Scheduling of gemcitabine and cisplatin in Lewis lung tumor bearing mice. Eur. J. Cancer, 35: 808-814, 1999.
16. Kufe, D. W., Major, P. P., Egan, E. M., and Beardsley, G. P. Correlation of cytotoxicity with incorporation of ara-C into DNA. J. Biol. Chem., 255: 8997-8900, 1980.
17. Huang, P., Chubb, S, and Plunkett, W. Termination of DNA synthesis by 9-beta-D-arabinofuranosyl-2-fluoroadenine: A mechanism for cytotoxicity. J. Biol. Chem., 265: 16617-16625, 1990.
18. Huang P., Chubb, S., Hertel, L. W., Gnndey, G. B., and Plunkett, W. Action of 2′, 2′-difluorodeoxycytidine on DNA synthesis. Cancer Res., 57: 6110-6117, 1991.
19. Ross, D. D., and Cuddy, D. P. Molecular effects of 2′,2′-difluorodeoxycytidine (gemcitabine) on DNA replication in tact HL-60 cells. Biochem. Pharmacol., 48: 1619-1630, 1994.
20. Huang, P., and Plunkett, W. Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemother. Pharmacol., 36: 181-188, 1995.
21. Kufe, D. W., Weichselbaum, R., Egan, E. M., Dahlberg, W., and Fram, R. J. Lethal effects of 1-β-D-arabinofuranosylcytosine incorporation into deoxyribonucleic acid during ultraviolet repair. Mol. Pharmacol., 25: 322-326, 1984.
22. Yang, L.-Y., Li, L., Keating, M. J., and Plunkett, W. Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair. Mol. Pharmacol., 47: 1072-1079, 1995.
23. Sandoval, A., Consoli, U., and Plunkett, W. Fludarabine-mediated inhibition of nucleotide excision repair induces apoptosis in quiescent human lymphocytes. Clin. Cancer Res., 2: 1731-1742, 1996.
24. Li, L., Liu, X-m., Glassman, A. B., Keating, M. J., Stros, M., Plunkett, W., and Yang, L-Y. Fludarabine triphosphate inhibits nucleotide excision repair of cisplatin-induced DNA adducts in vitro. Cancer Res., 57: 1487-1494, 1997.
25. Iwasaki, H., Huang, P., and Plunkett, W. Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells. Blood, 90: 270-278, 1997.
26. Li, L., Keating, M. J., Plunkett, W., and Yang, L-Y. Fludarabinemediated inhibition of cisplatin-induced DNA lesions in chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance. Mol. Pharmacol., 52: 798-806, 1997.
27. Johnes, J., Zhen, W., Reed, E., Parker, R. J., Sancar, A., and Bohr, V. A. Gene-specific formation and repair of cisplatin intrastrand adducts and interstrand cross-links in Chinese hamster ovary cells. J. Biol. Chem., 266: 7101-7107 1991.
28. Sancar, A Excision repair in mammalian cells. J. Biol. Chem., 270: 15915-15918, 1995.
29. Thompson, L. H. Evidence that mammalian cells possess homologous recombinational repair pathways. Mutat. Res., 363: 77-88, 1996.
30. Johnson, S. W., Perez, R. P., Godwin, A. K., Yeung, A. T., Handel, L. M., Ozols, R. F., and Hamilton, T. C. Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines. Biochem. Pharmacol., 47: 689-697, 1994.
31. Calsou, P., Barret, J-M., Cros, S., and Salles, B. DNA excision-repair synthesis is enhanced in a murine leukemia L1210 cell line resistant to cisplatin. Eur. J. Biochem., 211: 403-409, 1993.
32. 4-methylthymine, or the cisplatin-d(GpG) adduct. Proc. Natl. Acad. Sci. USA, 93: 6443-6447, 1996.
33. Fink, D., Nebe, S., Aebi, S., Zheng, H., Cenni, B., Nehme, A., Christen, R. D., and Howell, S. B. The role of mismatch repair in platinum drug resistance. Cancer Res., 56: 4881-4886, 1996.
34. Fink, D., Zheng, H., Nebel, S., Norris, P. S., Aebi, S., Lin, T-P., Nehme, A., Christen, R. D., Haas, M., MacLeod, C. L., and Howell, S. B. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res., 57: 1841-1845, 1997.
35. Fink, D., Nebel S., Aebi, S., Nehme, A., and Howell, S. B. Loss of DNA mismatch repair due to knockout of MSH2 or PMS2 results in resistance to cisplatin and carboplatin. Int. J. Oncol., 11: 539-542, 1997.
36. Gong, J. G., Costanzo, A., Yang, H-Q., Melino, G., Kaelin, W. G., Levreri, M., and Wang, J. Y. J. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature (Lond.), 399: 806-809, 1999.
37. Vaisman, A., Varchenko, M., Umar, A., Kunkel, T. A., Risinger, J. I., Barrett, J. C., Hamilton, T. C., and Chaney, S. G. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: Correlation with replicative bypass of platinum-DNA adducts. Cancer Res., 58: 6443-6447, 1998.
38. Park, C-H., Bessho, T., Matsunaga, T., and Sancar, A. Purification and characterization of the XPF-ERCC1 complex of human DNA repair excision nuclease. J. Biol. Chem., 29: 22657-22660, 1995.
39. van Duin, M., de Wit, J., Odijk, H., Westerveld, A., Yasui, A., Koken, M. H. M., Hoeijmakers, J. H. J., and Bootsma, D. Molecular characterization of the human excision repair gene ERCC-1: cDNA cloning and amino acid homology with the yeast DNA repair gene RAD10. Cell, 44: 913-923, 1986.
40. Lee, K. B., Parker, R. J., Bohr, V., Cornelison, T., and Reed, E. Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3. Carcinogenesis (Lond.), 14: 2177-2180, 1993.
41. Collins, A. R. Mutant rodent cell lines sensitive to ultraviolet light, ionizing radiation and cross-linking agents: a comprehensive survey of genetic and biochemical characteristics. Mutat. Res., 29: 99-118, 1993.
42. Cartee, L., and Kucera, G. L. Gemcitabine induces programmed cell death and activates protein kinase C in BG-1 human ovarian cancer cells. Cancer (Phila.) Chemother. Pharmacol., 41: 403-412, 1998.
43. Ariza, R. R., Keyse, S. M., Moggs, J. G., and Wood, R. D. Reversible protein phosphorylation modulates nucleotide excision repair of damaged DNA by human extracts. Nucleic Acids Res., 24: 433-440, 1996.
44. Yang, L-Y., Trujillo, J. M., Siciliano, M. J., Kido, Y., Siddick, Z., and Su, Y-Z. Distinct P-glycoprotein expression in two subclones simultaneously selected from a human colon carcinoma cell line by cis-diamminedichloroplatinum(II). Int. J. Cancer, 53: 478-485, 1993.
45. Umar, A., Boyer, J. C., Thomas, D. C., Nguyen, D. C., Risinger, J. I., Boyd, J., Ionov, Y., Perucho, M., and Kunkel, T. A. Defective mismatch repair in extracts of colorectal and endometrial cancer cell lines exhibiting microsatellite instability. J. Biol. Chem., 269: 14367-14370, 1994.
46. Hansson, J., and Wood, R. D. Repair synthesis by human cell extracts in DNA damaged by cis- and trans-diamminedichloroplatinum (II). Nucleic Acids Res., 20: 8073-8091, 1989.
47. Chou, T-C., and Talay, P. Quantitative analysis of dose-effect relationship: The combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme. Regul., 22: 27-55, 1984.
48. neu1. Cancer Res, 56: 794-801, 1996.
49. Li, M.-J., and Yang, L.-Y. Use of novel plasmid constructs to demonstrate fludarabine triphosphate inhibition of nucleotide excision repair of a site-specific 1,2-d(GpG) intrastrand cisplatin adduct. Int. J. Oncol., 15: 1177-1183, 1999.
50. Perfetti, R., Lee-Kwon, W., Montrose-Rafizadeh, C., and Bernier, M. Overexpression and activation of the insulin receptor enhances expression of ERCC-1 messenger ribonucleic acid in cultured cells. The Endocrine Society, 138: 1829-1835, 1997.
51. Westerveld, A., Hoeijmakers, J. H. J., van Duin, M., de Wit, J., Odijk, H., Pastink, A., Wood, R. D., and Bootsma, D. Molecular cloning of a human DNA repair gene. Nature (Lond.), 310: 420-429, 1984.
52. Park, C-H., and Sancar, A. Formation of a ternary complex by human XPA, ERCC1, and ERCC4 (XPF) excision repair proteins. Proc. Natl. Acad. Sci. USA, 91: 5017-5021, 1994.
53. 1 -dependent mice show increased genome instability and a reduced frequency of S-phase-dependent illegitimate chromosome exchange but a normal frequency of homologous recombination. J. Cell Sci., 111: 395-404, 1998.
54. Li, L., Peterson, C. A., Lu, X., Wei, P., and Legerski, R. J. Interstrand cross-links induce DNA synthesis in damaged and undamaged plasmids in mammalian cell extracts. Mol. Cell. Biol., 19: 5619-5630, 1999.
55. Pil, P. M., and Lippard, S. J. Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin. Science (Washington DC), 256: 234-237, 1992.
56. Huang, J-C., Zambie, D. B., Reardon, J. T., Lippard, S. J., and Sancar, A. HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc. Natl. Acad. Sci. USA, 91: 10394-10398, 1994.
57. Yaneva, J., Leuba, S. H., van Holde, K., and Zlatanova, J. The major chromatin protein histone H1 binds preferentially to cisplatinum-damaged DNA. Proc. Natl. Acad. Sci. USA, 94: 13448-13451, 1997.
58. Grunewald, R., Kantarjian, H., Keating, M. J., Abbruzzese, J., Tarassoff, P., and Plunkett, W. Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (gemcitabine) administration in leukemia. Cancer Res., 50: 6823-6826, 1990.
59. Plunkett, W., Gandhi, V., Chubb, S., Nowak, B., Heinemann, V., Mineishi, S., Sen, A., Hertel, L. W., and Grindey, G. B. 2′,2′-difluorodeoxycytidine metabolism and mechanism of action in human leukemia cells. Nucleosides Nucleotides, 8: 775-785, 1989.
60. Heinemann, V., Xu, Y-Z., Chubb, S., Sen, A., Hertel, L. W., Grindey, G. B., and Plunkett, W. Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: A mechanism of self-potentiation. Cancer Res., 52: 533-539, 1992.
61. Gandhi, V., Legha, J., Chen, F., Hertel, L. W., and Plunkett, W. Excision of 2′,2′-difluorodeoxycytidine (gemcitabine) monophosphate residues from DNA. Cancer Res., 56: 4453-4459, 1996.